NCT04296305View on ClinicalTrials.gov

Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Interventions
DRUG

Hydromorphone

Given IV after

DRUG

Placebo Administration

Given IV after

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER